{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:07Z","timestamp":1794047467998,"version":"4.8.0"},"reference-count":25,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"8","license":[{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>In newly diagnosed acute myeloid leukemia (AML), immediate initiation of treatment is standard of care. However, deferral of antileukemic therapy may be indicated to assess comorbidities or pretherapeutic risk factors. We explored the impact of time from diagnosis to treatment on outcomes in newly diagnosed AML undergoing venetoclax-based therapy in two distinct cohorts. By querying the Study Alliance Leukemia database and the global health network TriNetX, we identified 138 and 717 patients respectively with an average age of 76 and 72 years who received venetoclax-based first-line therapy. When comparing patients who started treatment earlier or later than 10 days after initial diagnosis, no significant difference in median overall survival was observed - neither in the SAL cohort (7.7 vs. 9.6 months; P=0.42) nor in the TriNetX cohort (7.5 vs. 7.2 months; P=0.41). Similarly, severe infections, bleeding, and thromboembolic events were equally observed between early and later treatments, both in the overall patient groups and specific subgroups (age \u226575 years or leukocytes \u226520x109\/L). This retrospective analysis indicates that delaying the start of venetoclax-based therapy in newly diagnosed AML might be a safe option for selected patients, provided that close clinical monitoring is performed.<\/jats:p>","DOI":"10.3324\/haematol.2024.285225","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T03:06:31Z","timestamp":1713927991000},"page":"2469-2477","source":"Crossref","is-referenced-by-count":12,"title":["Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens"],"prefix":"10.3324","volume":"109","author":[{"given":"David","family":"Baden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Zukunft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Wolgast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Steinhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Pohlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schliemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Henrik","family":"Mikesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjorn","family":"Steffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher","family":"Hanoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Schafer-Eckart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan W.","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Hanel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Jost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim H.","family":"Brummendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Scholl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Neubauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Burchert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Niemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Schaich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Blau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gorner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Kullmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang E","family":"Berdel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Ehninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Muller-Tidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Serve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bornhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Rollig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia D","family":"Baldus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Fransecky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,4,24]]},"reference":[{"key":"64218","doi-asserted-by":"crossref","unstructured":"Burnett AK, Milligan D, Prentice AG. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007; 109(6):1114-1124.","DOI":"10.1002\/cncr.22496"},{"key":"64219","doi-asserted-by":"crossref","unstructured":"Burchenal JH, Murphy ML, Tan CTC. Treatment of acute leukemia. Pediatrics. 1956; 18(4):643-660.","DOI":"10.1542\/peds.18.4.643"},{"key":"64220","doi-asserted-by":"crossref","unstructured":"Sekeres MA, Elson P, Kalaycio ME. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood. 2009; 113(1):28-36.","DOI":"10.1182\/blood-2008-05-157065"},{"key":"64221","doi-asserted-by":"crossref","unstructured":"Stone RM, Mandrekar SJ, Sanford BL. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 Mutation. N Engl J Med. 2017; 377(5):454-464.","DOI":"10.1056\/NEJMoa1614359"},{"key":"64222","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022; 140(12):1345-1377.","DOI":"10.1182\/blood.2022016867"},{"key":"64223","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian RP. International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022; 140(11):1200-1228.","DOI":"10.1182\/blood.2022015850"},{"key":"64224","doi-asserted-by":"crossref","unstructured":"Khoury JD, Solary E, Abla O. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022; 36(7):1703-1719.","DOI":"10.1038\/s41375-022-01613-1"},{"key":"64225","doi-asserted-by":"crossref","unstructured":"Bertoli S, B\u00e9rard E, Huguet F. Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. Blood. 2013; 121(14):2618-2626.","DOI":"10.1182\/blood-2012-09-454553"},{"key":"64226","doi-asserted-by":"crossref","unstructured":"R\u00f6llig C, Kramer M, Schliemann C. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?. Blood. 2020; 136(7):823-830.","DOI":"10.1182\/blood.2019004583"},{"key":"64227","doi-asserted-by":"crossref","unstructured":"Juliusson G, Hagberg O, Lazarevic VL, Lehmann S, H\u00f6glund M. Impact of treatment delay in acute myeloid leukemia revisited. Blood Adv. 2021; 5(3):787-790.","DOI":"10.1182\/bloodadvances.2020003806"},{"key":"64228","doi-asserted-by":"crossref","unstructured":"Alsouqi A, Rothenberger SD, Boyiadzis M, Lontos K. Time from diagnosis to treatment is associated with survival in patients with acute myeloid leukemia: an analysis of 55,985 patients from the National Cancer Database. Br J Haematol. 2022; 199(2):256-259.","DOI":"10.1111\/bjh.18381"},{"key":"64229","doi-asserted-by":"crossref","unstructured":"Franco S, Geng X, Korostyshevskiy V, Karp JE, Lai C. Systematic review and meta-analysis: Prognostic impact of time from diagnosis to treatment in patients with acute myeloid leukemia. Cancer. 2023; 129(19):2975-2985.","DOI":"10.1002\/cncr.34894"},{"key":"64230","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Jonas BA, Pullarkat V. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020; 383(7):617-629.","DOI":"10.1056\/NEJMoa2012971"},{"key":"64231","doi-asserted-by":"crossref","unstructured":"Montesinos P, Recher C, Vives S. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022; 386(16):1519-1531.","DOI":"10.1056\/NEJMoa2117344"},{"key":"64232","doi-asserted-by":"crossref","unstructured":"Short NJ, Nguyen D, Ravandi F. Treatment of older adults with FLT3-mutated AML: emerging paradigms and the role of frontline FLT3 inhibitors. Blood Cancer J. 2023; 13(1):142.","DOI":"10.1038\/s41408-023-00911-w"},{"key":"64233","doi-asserted-by":"crossref","unstructured":"Palchuk MB, London JW, Perez-Rey D. A global federated real-world data and analytics platform for research. JAMIA Open. 2023; 6(2):ooad035.","DOI":"10.1093\/jamiaopen\/ooad035"},{"key":"64234","doi-asserted-by":"crossref","unstructured":"Liu C-J, Hong Y-C, Kuan AS. The risk of early mortality in elderly patients with newly diagnosed acute myeloid leukemia. Cancer Med. 2020; 9(4):1572-1580.","DOI":"10.1002\/cam4.2740"},{"key":"64235","doi-asserted-by":"crossref","unstructured":"Oberoi S, Lehrnbecher T, Phillips R. Early mortality in hyperleukocytosis in patients with acute myeloid leukemia: a systematic review and meta-analysis. Blood. 2013; 122(21):2647.","DOI":"10.1182\/blood.V122.21.2647.2647"},{"key":"64236","doi-asserted-by":"crossref","unstructured":"Rinaldi I, Sutandyo N, Winston K. Comparison of early mortality between leukapheresis and non-leukapheresis in adult acute myeloid leukemia patients with hyperleukocytosis: a systematic review and meta-analysis. Hematology. 2022; 27(1):141-149.","DOI":"10.1080\/16078454.2021.2024939"},{"key":"64237","doi-asserted-by":"crossref","unstructured":"Vachhani P, Flahavan EM, Xu T. Venetoclax and hypomethylating agents as first-line treatment in newly diagnosed patients with AML in a predominately community setting in the US. Oncologist. 2022; 27(11):907-918.","DOI":"10.1093\/oncolo\/oyac135"},{"key":"64238","doi-asserted-by":"crossref","unstructured":"Hoff FW, Patel PA, Belli AJ. Real-world outcomes of frontline venetoclax-based therapy in older adults with acute myeloid leukemia: an analysis utilizing EHR data. Leuk Lymphoma. 2023; 64(6):1123-1128.","DOI":"10.1080\/10428194.2023.2197090"},{"key":"64239","unstructured":"Ucar MA, Ozet G, Koyuncu MB. Real world results of venetoclax combined with hypomethylating agents in relapsed\/refractory AML. Eur Rev Med Pharmacol Sci. 2021; 25(21):6557-6565."},{"key":"64240","doi-asserted-by":"crossref","unstructured":"Gershon A, Ma E, Xu T. Early real-world first-line treatment with venetoclax plus HMAs versus HMA monotherapy among patients with AML in a predominately US community setting. Clin Lymphoma Myeloma Leuk. 2023; 23(5):e222-e231.","DOI":"10.1016\/j.clml.2023.02.002"},{"key":"64241","doi-asserted-by":"crossref","unstructured":"Ucciero A, Pagnoni F, Scotti L. Venetoclax with hypomethylating agents in newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis of survival data from real-world studies. Cancers. 2023; 15(18):4618.","DOI":"10.3390\/cancers15184618"},{"key":"64242","doi-asserted-by":"crossref","unstructured":"Liu F, Panagiotakos D. Real-world data: a brief review of the methods, applications, challenges and opportunities. BMC Med Res Methodol. 2022; 22(1):287.","DOI":"10.1186\/s12874-022-01768-6"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285225\/76915","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285225\/77339","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11564\/76915","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:06:17Z","timestamp":1794045977000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.285225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,24]]},"references-count":25,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285225","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3842022\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-3842022\/v2","asserted-by":"object"}]},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,24]]}}}